孟鲁司特钠与酮替酚治疗小儿咳嗽变异性哮喘对其咳嗽症状消失时间和呼吸功能指标恢复时间的影响  

Effect of Montelukast Sodium and Ketotifen in the Treatment of Pediatric Cough Variability Asthma on the Time of Cough Symptom Disappearance and the Time of Recovery of Respiratory Function Indicators

作　　者：王显敏[1] 陈松 陈云鸿 WANG Xianmin;CHEN Song;CHEN Yunhong(Department of Pediatric Internal Medicine,Zigong Fourth People's Hospital,Zigong,Sichuan Province,643000 China;Department of Pediatric Health Care,Zigong Fourth People's Hospital,Zigong,Sichuan Province,643000 China)

机构地区：[1]自贡市第四人民医院小儿内科,四川自贡643000 [2]自贡市第四人民医院儿童保健科,四川自贡643000

出　　处：《系统医学》2024年第10期150-153,161,共5页Systems Medicine

摘　　要：目的探讨小儿咳嗽变异性哮喘(Cough Variant Asthma,CVA)治疗中应用孟鲁司特钠与酮替酚的临床效果及对预后的影响。方法回顾性选取2022年1月—2023年9月自贡市第四人民医院收治的98例CVA患儿的临床资料,以治疗方法不同分为对照组和观察组,各49例。对照组单一应用孟鲁司特钠治疗,观察组合用孟鲁司特钠、酮替芬治疗。比较两组临床疗效、咳嗽症状消失时间、呼吸功能指标恢复时间、肺功能、炎症水平、免疫功能指标。结果观察组临床有效率为93.88%,高于对照组的79.59%,差异有统计学意义(χ^(2)=4.346,P<0.05)。与对照组比较,观察组咳嗽症状消失、呼吸功能指标恢复时间短,差异有统计学意义(P均<0.05)。治疗后两组第1秒用力呼气量、第1秒用力呼气量/用力肺活量、最大呼气峰流速均呈升高趋势,且观察组优于对照组,差异有统计学意义(P均<0.05)。两组治疗后肿瘤坏死因子-α、免疫球蛋白E、辅助性T细胞1检测值呈下降趋势,白细胞介素-4、调节性T细胞检测值呈升高趋势,且观察组优于对照组,差异有统计学意义(P均<0.05)。结论在小儿CVA治疗中孟鲁司特钠与酮替芬合用可取得确切疗效,可使咳嗽症状和呼吸功能得到改善改善,提高肺功能、缓解炎症水平。Objective To investigate the clinical effect of the application of montelukast sodium and ketotifen in the treatment of pediatric cough variant asthma(CVA)and its impact on prognosis.Methods The clinical data of 98 chil-dren with CVA admitted to the Fourth People's Hospital of Zigong City from January 2022 to September 2023 were retrospectively selected and divided into a control group and an observation group of 49 cases each with different treatment methods.The control group was treated with montelukast sodium alone,and the observation group was treated with montelukast sodium and ketotifen.The two groups were compared in terms of clinical efficacy,disappearance time of cough symptoms,recovery time of respiratory function indexes,lung function,inflammation level,and immune function indexes.Results The clinical efficacy rate in the observation group was 93.88%,which was higher than that of 79.59%in the control group,the difference was statistically significant(χ^(2)=4.346,P<0.05).Comparing with the con-trol group,the observation group's cough symptoms disappeared and the recovery time of respiratory function indexes were shorter,the differences were statistically significant(both P<0.05).The forced expiratory volume in one second,forced expiratory volume in one second/forced vital capacity,and peak expiratory flow of the two groups showed a ten-dency to increase after the treatment,and the observation group was better than the control group,the differences were statistically significant(all P<0.05).Tumor necrosis factor-α,immunoglobulin E,and helper Tcell 1 assay values showed a decreasing trend,and interleukin-4 and regulatory Tcell assay values showed an increasing trend after treat-ment in both groups,and the observation group was better than the control group,the differences were statistically sig-nificant(all P<0.05).Conclusion In the treatment of pediatric CVA,the combination of montelukast sodium and keto-tifen can achieve precise efficacy,which can improve cough symptoms and respiratory function,improv

关 键 词：孟鲁司特钠 酮替酚 咳嗽变异性哮喘 咳嗽症状消失时间 呼吸功能 

分 类 号：R4[医药卫生—临床医学]